Indeed, a series of mouse studies have demonstrated that MYCN can be an oncogenic driver for glioma, medulloblastoma, primitive neuroectoderm tumor, and neuroblastoma (9, 10, 56). This evidence concerns the gene MYCN and neuroblastoma.